tbuckley/cabot-search huggingface dataset:
AB0842-HPR The effect of core stability and flight time on low back pain in military helicopter pilots
Authors: O. Cinar Medeni, N. Atalay Guzel, M. Erdogan
Journal: Annals of the Rheumatic Diseases (2013)

<h3>Background</h3> It is known that helicopter pilots experience low back pain frequently <sup>1</sup>. underlying factors could be vibration created compressive forces <sup>2</sup> faulty movement mechanics, lack of abdominal strength, loss of flexibility, poor general health-fitness and poor posture<sup>3</sup>. Core stability parameters and flight time might be in relation to low back pain in helicopter pilots. <h3>Objectives</h3> The aim of this study is to investigate the effect of core stability and flight time on low back pain military pilots. <h3>Methods</h3> 21 pilots were assessed. Demographic information was recorded. Employment year and total flight time were recorded. McGill core endurance tests <sup>4</sup> and Oswestry low back pain disability questionnaire were done. Correlation analysis between Oswestry low back pain disability score and subjects’ year, employment year, total flight time and, core stability tests was done by using Spearman Correlation Co-efficient due to low number of subjects. <h3>Results</h3> A significant positive correlation between Oswestry low back pain disability score and subject’s year, employment year and total flight time were found, respectively (r=.55, p=.01; r=.52, p=.018; r=.53, p=.016). There were not any significant correlations between core endurance tests and Oswestry score (p&gt;.05) <h3>Conclusions</h3> Low back pain increases with age, employment year and total flight time in helicopter pilots. It shows that low back complaints are work-related in and not related to core muscle endurance. <h3>References</h3> Thomae MK, Porteous JE, Brock JR, Allen GD, Heller RF. Back pain in Australian military helicopter pilots: a preliminary study. <i>Aviat Space Environ Med.</i> 1998;69(5):468-473. de Oliveira CG, Nadal J. Transmissibility of Helicopter Vibration in the Spines of Pilots in Flight. <i>Aviation, Space, and Environmental Medicine.</i> 2005;76(6):576-580. Pelham TW, White H, Holt LE, Lee SW. The etiology of low back pain in military helicopter aviators: prevention and treatment. <i>Work.</i> 2005;24(2):101-110. McGill S. <i>Low Back Disorders. Evidence-Based Prevention and Rehabilitation.</i> Champaign: Human Kinetics; 2002. <h3>Disclosure of Interest</h3> None Declared
Endoscopic ultrasonography versus Helical computed tomography in preoperative TNM staging of gastric cancer
Authors: Zhu Liang-ru, Ding Zhen, Liu Shi, Chen Jie, Liu Jun, Hou Xiao-hua
Journal: Endoscopy (2011)

Objective: Endoscopic ultrasonography and helical computed tomography are very common examination in gastric cancer. This study was going to to evaluate the accuracy of endoscopic ultrasonography and helical computed tomography in preoperative TNM staging of gastric cancer.
Abstract A19: The effect of sunitinib on the production of cytokine in H460 tumor-bearing SCID mice.
Authors: Yung-Jen Tsai, Yuan-Jen Huang, Le-Mei Hong, Jia-Ming Chang
Journal: Cancer Research (2011)

Abstract Background: systemic inflammation is occurred patients with many different type of cancer which is associated with disease progression and therapeutic efficacy. The aim of this study was to investigate whether Interleukin 5 (IL-5), an interleukin produced by innate immune cells, and Interferon-gamma (INF-γ), the dimerized soluble cytokine produced by natural killer cells, may be stimulated by sunitinib in H460 tumor-bearing SCID mice. Methods: NCI-H460, a lung carcinoma cell line was inoculated in SCID mice subcutaneously. The H460 tumor-bearing mice were treated with sunitinib at a dose of 40 mg/kg by gavage one per day for 15 days. At the end of treatment, mice were sacrificed and blood was withdrawn for cytokine analysis by cytometric bead-based array (CBA). Results: results appeared that the tumor growth was inhibited by sunitinib treatment to 69.97 % inhibition. And with analysis of IL-5 and INF-γ, end levels of IL-5 and INF-γ were significantly enhanced which is correlated to sunitinib treatment. Summary: The results indicated that analyzing IL-5 and INF-γ in treatment might be used as prognosis biomarkers for cancer treatment. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the Second AACR International Conference on Frontiers in Basic Cancer Research; 2011 Sep 14-18; San Francisco, CA. Philadelphia (PA): AACR; Cancer Res 2011;71(18 Suppl):Abstract nr A19.
A2.06 Functional regulatory T-cells in rheumatoid arthritis bone marrow are modulated by IL-15 and strong antigenic stimulation
Authors: M Massalska, M Plebanczyk, A Radzikowska, E Kuca-Warnawin, M Prochorec-Sobieszek, U Musialowicz, U Skalska, W Kurowska, A Kornatka, T Burakowski, I Janicka, P Maldyk, E Kontny, W Maslinski
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background and objectives</h3> Role of CD4<sup>+</sup>Foxp3<sup>+</sup> regulatory T cells in control of autoimmune processes, including rheumatoid arthritis (RA) is well proved, however knowledge about Tregs functions in bone marrow (BM) is sparse. As concept of BM active participation in pathogenesis of RA is still developing, in the present work we compared the phenotype of Tregs in paired samples of bone marrow and peripheral blood from patients with RA and osteoarthritis (OA). Impact of IL-15, overexpressed in RA BM, on functional activity of BM Tregs was also investigated. <h3>Materials and methods</h3> <b>S</b>amples of BM and peripheral blood were obtained from RA and OA patients during hip replacement surgery. Tregs phenotype was assessed by FACS analysis and immunohistochemical staining. Bone marrow mononuclear cells were cultured with or without IL-15 before functional assays were done (measurement of cells proliferation and cytokines production). Data are shown as mean ± SEM. <h3>Results</h3> Treg cells isolated from BM and peripheral blood shared phenotype of memory CD45RO<sup>+</sup> cells, with significantly higher proportion of activated CD4<sup>+</sup>Foxp3<sup>+</sup>CD127<sup>+</sup> cells and lower proportion of CXCR4<sup>+ </sup>Tregs in RA BM. Tregs from OA and RA BM as well as from blood of healthy blood donors were functional and suppressed proliferation and cytokines production in coculture with effector T cells. Stronger signal mediated by anti-CD3/CD28 Abs sustained functionality only in RA Treg. After IL-15 treatment, suppression of proliferation by Tregs from OA BM was broken by stronger TCR signal. In contrast, RA Tregs functionality was maintained only when additionally stimulation by anti-CD3/CD28 Abs was supplied (63.3%±6.6%; p = 0.028 and 54.0%±6.1%; p = 0.067 respectively). Despite active suppression RA Tregs pre-stimulated by IL-15 and cultured in presence of anti-CD3/CD28 Abs produced significantly more TNF then Treg from blood of healthy blood donors (42.6 ± 7.4 vs 17.1 ± 5.7; p = 0.028) and OA BM (42.6 ± 7.4 vs 21.0 ± 8.6; ns). Pre-stimulation of the culture by IL-15 did not increase proportion of CD4<sup>+</sup>Foxp3<sup>+</sup>CXCR4<sup>+</sup> in any patients groups. <h3>Conclusions</h3> Phenotype and activation status of Tregs present in RA BM are influenced by locally overexpressed IL-15 that finally may contribute to RA pathogenesis, especially in context of TNF production and poor retention of Treg in BM compartment.
Pulmonary Function after Segmental Pulmonary Resection for Bronchiectasis
Authors: Benjamin E. Etsten, Richard H. Overholt, James H. Walker, Robert N. Reynolds
Journal: New England Journal of Medicine (1953)

SEGMENTAL pulmonary resection for bronchiectasis is based on the concept that it is most advantageous to conserve all healthy tissue and limit resection to the specific pulmonary segments destroyed by the disease.Bronchiectasis may affect any of the eighteen segments of the two lungs. In the majority of cases the disease does not involve the entire group of segments that constitutes a pulmonary lobe. Frequently, the disease is bilateral. It has been noted that the superior segment of both lower lobes and the two top segments of the left upper and right upper lobes are not often involved. When bronchiectasis . . .
Abstract 1954: In vitro effects on gene expression of Casp9, GRB10, and CDKN1B following rG3 treatment of human breast cancer cells
Authors: Katie Schalkoff, Heather Walker, Tom Scott
Journal: Cancer Research (2011)

Abstract Introduction: Integrins can stimulate cellular growth and proliferation, as well as apoptosis, and are important factors in AKT cell signaling. To assess their binding, a recombinant protein of the G3 domain of laminin-5 (rG3) that specifically binds the alpha subunit expressed on metastatic MDA-MB-231 cells in vitro was produced. Studying changes in expression of genes involved in cell signaling and the apoptosis cascade, specifically CDKN1B, GRB10, and Caspase 9, can help improve understanding of signaling pathways of metastatic cells and the AKT pathway. Methods: rG3 was produced using ArcticExpress Competent Cells (Stratagene). Plasmid DNA was transformed into competent cells and transferred to ampicillin plates for colony production of successful transformation. A single colony was used to inoculate LB broth containing gentamycin and ampicillin for an overnight incubation at 37°C. LB without antibiotics was inoculated with the overnight culture and incubated at 30°C for 3 hours. The temperature was lowered to 11.5°C before the expression was induced using IPTG at a final concentration of 1mM. SDS-PAGE/immunoblotting confirmed successful soluble rG3 protein expression. MDA-MB-231 human breast cancer cells from ATCC were grown in tissue culture flasks and maintained until confluent. Cells were plated at 3 × 106 cells/well in a 6-well tissue culture plate in a 2 ml volume of DMEM without pen/strep in duplicate. rG3 was added to wells at a final concentration of 175 µg/ml for treated cells and corresponding control buffer for untreated cells. After incubation overnight, cells were collected at time points within 0-60 hours and RNA was isolated using Qiagen RNeasy. An eppendorf Realplex 96-well plate reader was used for PCR analysis using a β-actin standard curve. Differences in gene expression were shown in fold change using Pfaffl's Method. Results: Our preliminary data show there are changes in gene expression after treatment with rG3.We are further investigating these changes in expression. Preliminary results suggest that changes in gene expression after treatment may be informative in understanding the AKT signaling pathway. Conclusion: The study of these changes in gene expression after altering the AKT pathway from treatment with rG3 could prove to be a helpful tool in understanding the signaling mechanisms of metastatic cells and the details of the signaling pathways involved in apoptosis. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2011;71(8 Suppl):Abstract nr 1954. doi:10.1158/1538-7445.AM2011-1954
AB0108 BETA-1 integrin is a critical mediator of TLR2-induced cell migration and invasion in RA
Authors: T. McGarry, M. Connolly, W. Gao, J. McCormick, D. Veale, U. Fearon
Journal: Annals of the Rheumatic Diseases (2013)

<h3>Background</h3> Inflammatory arthritis (IA) is a chronic disease characterised by inflammation and proliferation of synovial tissue, leading to progressive degradation of articular cartilage and bone. <h3>Objectives</h3> This aim of this study was to investigate the role of β1-integrin in mediating TLR2-induced cytoskeletal rearrangement, cell migration and invasion processes <i>in vitro</i>. <h3>Methods</h3> β-integrin expression (β1-4, β6, avβ5, a5β1), cytoskeletal rearrangement and RhoGTPase Rac1 activation in response to PAM3Cysk4 (1μg/ml) (TLR2-ligand) were assessed by a multiplex adhesion binding assay, F-actin immunofluorescent staining and Rac-1 pull down assays/Western blot. Pam3CSK4 induced cell migration, invasion and Rac1 activation was assessed by wound repair assays, transwell matrigel™ invasion chambers and Pulldown/western blot in the presence or absence of anti-β1 integrin (10μg/ml) or IgG control antibody (10μg/ml). <h3>Results</h3> Pam3CSK4 specifically induced β1-integrin binding (p&lt;0.05), with no effect observed for β2-4, β6, avβ5 or a5β1. Pam3CSK4 induced cytoskeletal disassembly, inducing microspike and filopodia formation. Furthermore Pam3CSK4 induced Rac1 activation, which is critically involved in cytoskeletal dynamics and cell movement. At a functional level Pam3CSK4 induced cell migration and invasion of RASFC (p&lt;0.05). Pam3CSK4-regulated cell migration and invasion processes were inhibited in the presence of anti-β1 integrin (p&lt;0.05), with no effect observed for IgG control. Furthermore Pam3CSK4 induced Rac-1 activation was also inhibited in the presence of anti-β1 integrin. <h3>Conclusions</h3> TLR2 activation induces cell migrational and invasive mechanisms which are specifically mediated through β1-integrin-induced cytoskeletal pathways. <h3>Disclosure of Interest</h3> T. McGarry: None Declared, M. Connolly: None Declared, W. Gao: None Declared, J. McCormick: None Declared, D. Veale Grant/Research support from: Wyeth, GSK, Abbott, Opsona, Consultant for: Wyeth, GSK, Abbott, Pfizer, Schering Plough, Centocor, Speakers Bureau: Wyeth, GSK, Abbott, Pfizer. Schering Plough, Centocor, Mundipharma, U. Fearon: None Declared
Indian doctor is arrested for not attending court hearing 24 years ago
Authors: Ingrid Torjesen
Journal: BMJ (2016)

A senior doctor, who tended to injured people after a workers’ uprising almost a quarter of a century ago, has been arrested in India.

On 1 July 1992, Saibal Jana, chief physician at Shaheed Hospital in Balod district, Chhattisgarh, was present at a workers’ rights rally where police opened fire, killing 18 people. He was …
832 MONITORING OF FACTORS RELATED TO PLASMA CONCENTRATION OF RIBAVIRIN COULD IMPROVE RESPONSE TO ANTIVIRAL THERAPY IN CHRONIC HEPATITIS C GENOTYPE 1
Authors: F.M. Jiménez Macías, S. Rodríguez-Novoa, E. Alvárez Barco, J. Morello Bullón, O. Ferna'ndez Codejón, F. Barrero Alor, M. Ramos Lora, L. Galisteo Almeda, C. Ruíz-Frutos, E. Pujol de la Llave, J. Conde-García, M.V. Salinas-Martín, J.L. Robles Rodríguez, R. González Gutíerrez, H. Pallarés Manrique, M.A.N. Fabis
Journal: Journal of Hepatology (2013)
677 PREDICTABILITY OF PREOPERATIVE [18F]FLUORODEOXYGLUCOSE POSITRON EMISSION TOMOGRAPHY FOR POSTOPERATIVE HISTOPATHOLOGIC DIFFERENTIATION AND EARLY TUMOR RECURRENCE OF PRIMARY MALIGNANT INTRAHEPATIC TUMORS
Authors: J.Y. Song, Y.S. Kim, S.J. Jin, E.H. Moon, J.M. Park, M.H. Choi, Y.N. Lee, D.C. Kim, S.G. Kim, H.J. Choi, J.H. Moon, S.H. Lee, S.W. Jeong, J.Y. Jang, H.S. Kim, B.S. Kim
Journal: Journal of Hepatology (2013)
Case 17-2015
Authors: Mihir M. Kamdar, Kathleen P. Doyle, Lecia V. Sequist, Todd J. Rinehart, Guy Maytal, Efren J. Flores, Mari Mino-Kenudson
Journal: New England Journal of Medicine (2015)

Hospital as a teaching exercise or reference material is now eligible to receive a complete set of PowerPoint slides, including digital images, with identifying legends, shown at the live Clinicopathological Conference (CPC) that is the basis of the Case Record.This slide set contains all of the images from the CPC, not only those published in the Journal.Radiographic, neurologic, and cardiac studies, gross specimens, and photomicrographs, as well as unpublished text slides, tables, and diagrams, are included.Every year 40 sets are produced, averaging 50-60 slides per set.Each set is supplied on a compact disc and is mailed to coincide with the publication of the Case Record.
Natural killer cell immunotherapy to target stem-like tumor cells
Authors: Steven K. Grossenbacher, Robert J. Canter, William J. Murphy
Journal: Journal for ImmunoTherapy of Cancer (2016)

Advances in cancer immunotherapy are leading to its increasing and successful application for the treatment of solid-tissue cancers. Despite the recent advances there are still significant barriers, in particular, evidence for significant tumor heterogeneity, both genetic and epigenetic that limit long-term efficacy. Subpopulations of "stem-like" tumor cells have been identified in nearly all human malignancies based on both morphologic and functional criteria. Also called cancer stem cells or CSCs, these quiescent cells display enhanced tumorigenic potential and are capable of repopulating tumors in the wake of traditional cytoreductive therapies. These CSCs may be best targeted via immunotherapy. Our lab has identified activated natural killer (NK) cell-based therapy as an effective method to target CSCs particularly after radiation therapy for solid tumors. Using a variety of in vitro and in vivo methods, including the utilization of primary tumor tissue and patient-derived xenografts, we observed that autologous and allogeneic NK cells possess the ability to preferentially kill stem-like cells or CSCs from freshly isolated patient samples representing a broad spectrum of tumor types, including pancreatic cancers, breast cancers, and sarcomas. The results indicated that CSCs express stress ligand molecules capable of being targeted by NKG2D on NK cells and that prior radiation therapy can both deplete the cycling non-CSCs bulk tumor population and upregulate these stress ligands on the CSC making this an effective combination approach.
Early Duodenogastric Reflux in Tc-99m Tetrofosmin Myocardial Scintigraphy: A Case Report
Authors: BINNUR KARAYALCIN, ADIL BOZ, FIRAT GÜNGÖR
Journal: Clinical Nuclear Medicine (1998)

Tc-99m tetrofosmin has been used widely as a cardiac imaging agent with favorable characteristics. Most protocols include imaging 15 to 30 min after intravenous injection of Tc-99m tetrofosmin. It is mainly excreted by the hepatobiliary system. Although cases with duodenogastric reflux have been reported with MIBI in the waiting period, no cases with tetrofosmin were found in the literature. The authors report a case with significant duodenogastric reflux of Tc-99m tetrofosmin that occurred during the acquisition period of exercise SPECT myocardial imaging.
AB0668 Effectiveness of individually tailored treatments in lupus nephritis: Data from 46 consecutive italian patients followed in a single center
Authors: G.A. Ramirez, G. Bonavida, V. Canti, P. Rovere-Querini, A.A. Manfredi, M.G. Sabbadini, E. Bozzolo
Journal: Annals of the Rheumatic Diseases (2013)

<h3>Background</h3> Lupus nephritis is a major cause of morbidity and mortality among lupus patients [1]. Despite the large number of studies demonstrating the efficacy of immunosuppressive therapies [2-3], universal therapeutic guidelines haven't yet been developed to date. Moreover the clinical polymorphism of lupus nephritis dampens the application of rigid therapeutic protocols and stress the need for individually tailored treatments. <h3>Objectives</h3> To assess the clinical outcome of a set of consecutive patients, receiving individually tailored treatments for their lupus nephritis. <h3>Methods</h3> Clinical data (including hypertension, complement consumption, urinary sediment abnormalities, serum creatinine values and ongoing therapies) of 46 consecutive patients with lupus nephritis from a single reference center were recorded between 1992 and 2011 at baseline, at 6, 18 months and at the end of the follow up. Patients with class III/IV/V lupus nephritis were included. <h3>Results</h3> Induction therapy with monthly cyclophosphamide (n=42) or mycophenolate (n=4) was performed during the first six months with a 30.4% rate of clinical remission. Patients who failed to achieve remission were maintaned with i.v. cyclophosphamide or shifted to mycophenolate and rituximab. Patients with persistent proteinuria received additional cyclosporin A [2]. Drug-related toxicity was reduced by bladder and gonad prophylaxis. Patients achieving sustained remission were shifted to azathioprine, mycophenolate or to therapy suspension. Nephritic reactivation was observed at least once in nine patients (19.6%). Mycophenolate or cyclophosphamide alone or in combination with cyclosporin and rituximab were used in patients who failed to achieve remission. Remission rates of 71.7% and 76.1% were obtained at 18 months and at follow up end respectively. Kidney survival was 100% at 18 months and 97.8% at the end of the follow-up. Complications occurred in 16/46 patients (34.8%). <h3>Conclusions</h3> These data demonstrate that combinations of available therapeutic tools induce sustained clinical remission and low drug-related toxicity in patients with lupus nephritis. Further studies are necessary to elucidate the underlying factors conferring each individual her/his unique response profile to different treatments at different disease times. <h3>References</h3> Isenberg, D. and P. Lesavre, Lupus, 2007. 16(3): p. 210-1. Ferrario, L., et al., Rheumatology (Oxford), 2000. 39(2): p. 218-220. Appel, G.B., et al., Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis. J Am Soc Nephrol, 2009. 20(5): p. 1103-12. <h3>Disclosure of Interest</h3> None Declared
MIND THE GAP: PALLIATIVE CARE KNOWLEDGE AMONG CARDIOVASCULAR CLINICIANS
Authors: Craig Alpert, Ellen Hummel, Scott Hummel, Kimberlee Gauvreau, Kelli Bohannon, Stephanie Cooper, Sarah Goodlin, Richard Josephson, Kelly Ann Light-McGroary, Keith Swetz, Paul Hauptman, Abby Cestoni, Mathew Maurer, Jorge Brenes Salazar, Caroline Doherty, Elizabeth Blume, James Kirkpatrick
Journal: Journal of the American College of Cardiology (2016)
Abstract 5143: ErbB2 activation up-regulates glutaminase 1 expression via NF-κB pathway
Authors: Shuo Qie, Clarissa Chu, Weihua Li, Chenguang Wang, Mauricio Reginato, Nianli Sang
Journal: Cancer Research (2012)

Abstract Active glutamine utilization is essential for cell proliferation in many tumors, for it provides critical carbon and nitrogen sources. Glutaminolysis represents the first and rate-limiting step of glutamine utilization and is catalyzed by glutaminase. Previous studies have shown that c-Myc regulates glutaminolysis by increasing glutaminase expression in tumor cells. However, it remains unclear whether other oncogenic signaling pathways promote glutaminolysis. Breast cancer is the second most common cause of death for women in the United States and ErbB2 activation is one of the major causes of breast cancer. Using MCF10A and MCF10A-derived NeuT cells, we studied the effect of ErbB2 activation on glutaminase expression, and found that ErbB2 activation increased glutaminase 1 expression at both mRNA and protein levels. Knockdown of ErbB2 decreased glutaminase 1 expression in several human ErbB2-positive cell lines. Consistently, blocking ErbB2 signaling pathway by trastuzumab repressed glutaminase 1 expression. We further showed that in these cells, ErbB2-mediated up-regulation of glutaminase 1 was independent of c-Myc expression. In addition, we found that activation of PI3K/Akt or MAPK pathway was not sufficient to up-regulate glutaminase 1 expression. Instead, inhibition of NF-κB down-regulated glutaminase 1 expression whereas stimulation of NF-κB induced glutaminase 1 expression, suggesting a PI3K/Akt-independent activation of NF-κB signaling pathway up-regulates glutaminase 1. Finally, inhibition of glutaminase activity significantly decreased human breast cancer cell proliferation. Our data indicate that ErbB2 activation promotes glutaminase 1 expression via NF-κB in breast cancer cells, identifying another oncogenic signaling pathway which stimulates glutamine utilization. These findings may facilitate the identification of novel targets for cancer therapy. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr 5143. doi:1538-7445.AM2012-5143